Ann MacDougall

Ann MacDougall is a highly accomplished professional with extensive experience in leadership and governance across various sectors. Currently, MacDougall serves as the Chairperson of the Board at Mazzetti, a benefit corporation focused on engineering solutions for climate change. Additionally, MacDougall holds positions as a Board Member Designee and Consultant at Alopexx Pharmaceuticals, Investment Committee Member at Builders Fund, and Co-Founder and CEO of Dunollie Fund, which invests in impact-driven initiatives. Previous roles include Board Member at Opiant Pharmaceuticals and ATMOS, and Interim Chair of the Board at Progenics Pharmaceuticals, where MacDougall successfully led the sale of the company. MacDougall has also served as President of Encore.org and held a leadership role at Acumen, overseeing global operations. Educational credentials include a JD from Brooklyn Law School and a BA in Theatre from Tufts University, complemented by a fellowship at Harvard University's Advanced Leadership Initiative.